These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 28348150)

  • 1. Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors.
    Pham LV; Ramirez S; Carlsen THR; Li YP; Gottwein JM; Bukh J
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.
    Gottwein JM; Jensen SB; Serre SB; Ghanem L; Scheel TK; Jensen TB; Krarup H; Uzcategui N; Mikkelsen LS; Bukh J
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6034-49. PubMed ID: 24060868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.
    Gottwein JM; Jensen SB; Li YP; Ghanem L; Scheel TK; Serre SB; Mikkelsen L; Bukh J
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1291-303. PubMed ID: 23274664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.
    Gottwein JM; Scheel TK; Jensen TB; Ghanem L; Bukh J
    Gastroenterology; 2011 Sep; 141(3):1067-79. PubMed ID: 21699793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of nucleotides in the 5'UTR and amino acids substitutions that are essential for the infectivity of 5'UTR-NS5A recombinant of hepatitis C virus genotype 1b (strain Con1).
    Li J; Feng S; Liu X; Guo M; Chen M; Chen Y; Rong L; Xia J; Zhou Y; Zhong J; Li YP
    Virology; 2018 May; 518():253-263. PubMed ID: 29549787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs.
    Gottwein JM; Scheel TK; Jensen TB; Lademann JB; Prentoe JC; Knudsen ML; Hoegh AM; Bukh J
    Hepatology; 2009 Feb; 49(2):364-77. PubMed ID: 19148942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations.
    Scheel TK; Gottwein JM; Carlsen TH; Li YP; Jensen TB; Spengler U; Weis N; Bukh J
    J Virol; 2011 Mar; 85(6):2891-906. PubMed ID: 21177811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus.
    Chen M; Xu Y; Li N; Yin P; Zhou Q; Feng S; Wu T; Wei L; Wang H; Fu Y; Li YP
    J Gen Virol; 2021 Dec; 102(12):. PubMed ID: 34949310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors.
    Ramirez S; Li YP; Jensen SB; Pedersen J; Gottwein JM; Bukh J
    Hepatology; 2014 Feb; 59(2):395-407. PubMed ID: 23913364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.
    Scheel TK; Gottwein JM; Mikkelsen LS; Jensen TB; Bukh J
    Gastroenterology; 2011 Mar; 140(3):1032-42. PubMed ID: 21111742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77.
    Li YP; Ramirez S; Mikkelsen L; Bukh J
    J Virol; 2015 Jan; 89(1):811-23. PubMed ID: 25355880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A.
    Gottwein JM; Jensen TB; Mathiesen CK; Meuleman P; Serre SB; Lademann JB; Ghanem L; Scheel TK; Leroux-Roels G; Bukh J
    J Virol; 2011 Sep; 85(17):8913-28. PubMed ID: 21697486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.
    Asante-Appiah E; Curry S; McMonagle P; Ingravallo P; Chase R; Nickle D; Qiu P; Howe A; Lahser FC
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
    Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
    J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6.
    Imhof I; Simmonds P
    J Virol; 2010 May; 84(9):4597-610. PubMed ID: 20164226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
    Pham LV; Ramirez S; Gottwein JM; Fahnøe U; Li YP; Pedersen J; Bukh J
    Gastroenterology; 2018 Jun; 154(8):2194-2208.e12. PubMed ID: 29454794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
    Suzuki F; Sezaki H; Akuta N; Suzuki Y; Seko Y; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Watahiki S; Miyakawa Y; Kumada H
    J Clin Virol; 2012 Aug; 54(4):352-4. PubMed ID: 22658798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system.
    Li YP; Ramirez S; Jensen SB; Purcell RH; Gottwein JM; Bukh J
    Proc Natl Acad Sci U S A; 2012 Nov; 109(48):19757-62. PubMed ID: 23151512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an Infectious Cell Culture System for Hepatitis C Virus Genotype 6a Clinical Isolate Using a Novel Strategy and Its Sensitivity to Direct-Acting Antivirals.
    Chen M; Zheng F; Yuan G; Duan X; Rong L; Liu J; Feng S; Wang Z; Wang M; Feng Y; Zhou Q; Li J; Deng K; Li C; Xia J; Rao G; Zhou Y; Fu Y; Li YP
    Front Microbiol; 2018; 9():2950. PubMed ID: 30564209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.